Eisai
In Brief This Week: Devyser, Danaher, Beacon Therapeutics, Care Access, IASO Biotherapeutics
News items for the week of Jan. 27, 2025.
At Some Hospitals, Expert Panels Help Guide Anti-Amyloid Drug Decisions for Alzheimer's Patients
Premium
These boards are cropping up around the US as neurologists acclimate to a new class of drugs, but not everyone agrees such programs are necessary.
Eisai, Biogen's Leqembi Receives FDA Approval for Chronic Alzheimer's Maintenance Treatment
With this approval, patients who receive the anti-amyloid drug biweekly for 18 months can then consider switching to a monthly dosing regimen.
Despite Leqembi's initial slow sales, the firm's CEO cited areas for the drug's growth and ambitions for an antisense oligonucleotide candidate targeting tau.
FDA Accepts Eisai's BLA for Subcutaneous Leqembi Maintenance Dosing
The agency expects to issue a decision by Aug. 31, and it is slated to decide on maintenance dosing for an intravenous form of the drug later this month.
Jul 31, 2024
Jul 29, 2024